Cargando…
Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
(1) Background: Efavirenz plasma concentration displays wide between-patient variability partly due to pharmacogenetic variation and autoinduction. Pediatric data on efavirenz pharmacokinetics and the relevance of pharmacogenetic variation are scarce, particularly from sub-Saharan Africa, where >...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707067/ https://www.ncbi.nlm.nih.gov/pubmed/34945777 http://dx.doi.org/10.3390/jpm11121303 |
_version_ | 1784622346226630656 |
---|---|
author | Chala, Adugna Tadesse, Birkneh Tilahun Chaka, Tolossa Eticha Mukonzo, Jackson Kitabi, Eliford Ngaimisi Tadesse, Sintayehu Pohanka, Anton Makonnen, Eyasu Aklillu, Eleni |
author_facet | Chala, Adugna Tadesse, Birkneh Tilahun Chaka, Tolossa Eticha Mukonzo, Jackson Kitabi, Eliford Ngaimisi Tadesse, Sintayehu Pohanka, Anton Makonnen, Eyasu Aklillu, Eleni |
author_sort | Chala, Adugna |
collection | PubMed |
description | (1) Background: Efavirenz plasma concentration displays wide between-patient variability partly due to pharmacogenetic variation and autoinduction. Pediatric data on efavirenz pharmacokinetics and the relevance of pharmacogenetic variation are scarce, particularly from sub-Saharan Africa, where >90% of HIV-infected children live and population genetic diversity is extensive. We prospectively investigated the short- and long-term effects of efavirenz auto-induction on plasma drug exposure and the influence of pharmacogenetics among HIV-infected Ethiopian children. (2) Method: Treatment-naïve HIV-infected children aged 3–16 years old (n = 111) were enrolled prospectively to initiate efavirenz-based combination antiretroviral therapy (cART). Plasma efavirenz concentrations were quantified at 4, 8, 12, 24, and 48 weeks of cART. Genotyping for CYP2B6, CYP3A5, UGT2B7, ABCB1, and SLCO1B1 common functional variant alleles was performed. (3) Results: The efavirenz plasma concentration reached a peak at two months, declined by the 3rd month, and stabilized thereafter, with no significant difference in geometric mean over time. On average, one-fourth of the children had plasma efavirenz concentrations ≥4 µg/mL. On multivariate analysis, CYP2B6*6 and ABCB1c.3435 C > T genotypes and low pre-treatment low-density lipoprotein (LDL) were significantly associated with higher plasma efavirenz concentration regardless of treatment duration. Duration of cART, sex, age, nutritional status, weight, and SLCO1B, CYP3A5, UGT2B7, and ABCB1 rs3842 genotypes were not significant predictors of efavirenz plasma exposure. (4) Conclusion: Pre-treatment LDL cholesterol and CYP2B6*6 and ABCB1c.3435 C > T genotypes predict efavirenz plasma exposure among HIV-infected children, but treatment-duration-dependent changes in plasma efavirenz exposure due to auto-induction are not statistically significant. |
format | Online Article Text |
id | pubmed-8707067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87070672021-12-25 Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study Chala, Adugna Tadesse, Birkneh Tilahun Chaka, Tolossa Eticha Mukonzo, Jackson Kitabi, Eliford Ngaimisi Tadesse, Sintayehu Pohanka, Anton Makonnen, Eyasu Aklillu, Eleni J Pers Med Article (1) Background: Efavirenz plasma concentration displays wide between-patient variability partly due to pharmacogenetic variation and autoinduction. Pediatric data on efavirenz pharmacokinetics and the relevance of pharmacogenetic variation are scarce, particularly from sub-Saharan Africa, where >90% of HIV-infected children live and population genetic diversity is extensive. We prospectively investigated the short- and long-term effects of efavirenz auto-induction on plasma drug exposure and the influence of pharmacogenetics among HIV-infected Ethiopian children. (2) Method: Treatment-naïve HIV-infected children aged 3–16 years old (n = 111) were enrolled prospectively to initiate efavirenz-based combination antiretroviral therapy (cART). Plasma efavirenz concentrations were quantified at 4, 8, 12, 24, and 48 weeks of cART. Genotyping for CYP2B6, CYP3A5, UGT2B7, ABCB1, and SLCO1B1 common functional variant alleles was performed. (3) Results: The efavirenz plasma concentration reached a peak at two months, declined by the 3rd month, and stabilized thereafter, with no significant difference in geometric mean over time. On average, one-fourth of the children had plasma efavirenz concentrations ≥4 µg/mL. On multivariate analysis, CYP2B6*6 and ABCB1c.3435 C > T genotypes and low pre-treatment low-density lipoprotein (LDL) were significantly associated with higher plasma efavirenz concentration regardless of treatment duration. Duration of cART, sex, age, nutritional status, weight, and SLCO1B, CYP3A5, UGT2B7, and ABCB1 rs3842 genotypes were not significant predictors of efavirenz plasma exposure. (4) Conclusion: Pre-treatment LDL cholesterol and CYP2B6*6 and ABCB1c.3435 C > T genotypes predict efavirenz plasma exposure among HIV-infected children, but treatment-duration-dependent changes in plasma efavirenz exposure due to auto-induction are not statistically significant. MDPI 2021-12-05 /pmc/articles/PMC8707067/ /pubmed/34945777 http://dx.doi.org/10.3390/jpm11121303 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chala, Adugna Tadesse, Birkneh Tilahun Chaka, Tolossa Eticha Mukonzo, Jackson Kitabi, Eliford Ngaimisi Tadesse, Sintayehu Pohanka, Anton Makonnen, Eyasu Aklillu, Eleni Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study |
title | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study |
title_full | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study |
title_fullStr | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study |
title_full_unstemmed | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study |
title_short | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study |
title_sort | predictors of efavirenz plasma exposure, auto-induction profile, and effect of pharmacogenetic variations among hiv-infected children in ethiopia: a prospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707067/ https://www.ncbi.nlm.nih.gov/pubmed/34945777 http://dx.doi.org/10.3390/jpm11121303 |
work_keys_str_mv | AT chalaadugna predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT tadessebirknehtilahun predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT chakatolossaeticha predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT mukonzojackson predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT kitabielifordngaimisi predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT tadessesintayehu predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT pohankaanton predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT makonneneyasu predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy AT aklillueleni predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy |